An economic evaluation published in the Indian Journal of Medical Research has demonstrated that shorter, six-month all-oral treatment regimens for multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) are cost-effective and offer improved health outcomes compared to the c
A newly released Global Antimicrobial Resistance Surveillance Report 2025 highlights widening disparities, with low and middle-income nations disproportionately affected. According to the report, resistance was most prevalent in the WHO South-East Asia and Eastern Mediterranean regions in 20
Ridalin Shullai, a TB survivor, shares her emotional journey of battling multi-drug resistant tuberculosis (MDR-TB), the loss of a lung, and the stigma surrounding the disease. She also highlights the need for counseling and support for TB patients.
The BPaLM regimen is a novel treatment for multi-drug-resistant tuberculosis (MDR-TB) under its National TB Elimination Programme (NTEP) as a highly effective and shorter treatment option.
Experts are developing revolutionary immune-enhancing medicines known as host-directed therapies, which employ the body's immune system to target TB, to tackle even drug-resistant strains of the illness.
According to research, the survival rate in children with drug-resistant epilepsy (DRE) was highest following cranial epilepsy surgery and lowest when treated simply with antiseizure medicines.
Researchers at the University of Otago have discovered new treatment possibilities for antibiotic-resistant tuberculosis (TB) strains, clearing the path for new tactics to tackle the disease that takes the lives of around 4,000 people every day.
New treatment options for tuberculosis (TB) strains that are resistant to antibiotics have been found by University of Otago researchers, paving the way for fresh strategies to combat the illness that claims the lives of approximately 4,000 people daily.